Detect altered DNA
With ~90% sensitivity and ~99% negative predictive value at detecting Barrett's esophagus and esophageal adenocarcinoma, the EsoGuard test allows detection of these conditions in a simple office-based procedure without endoscopy.
1
1,2,3
408
patient human study
published in
Science Translational Medicine
1
>90%
sensitivity & specificity
at detecting BE, with and without dysplasia, as
well as esophageal adenocarcinoma
1
How it works
Distal esophageal cells are sampled in a simple office-based procedure, shipped in preservative with the provided mailer, and processed at our laboratory. Results are typically available within 3 weeks.
01
Cell Collection
Distal esophageal cells are sampled in a simple office-based procedure and sent to our laboratory.
02
Test
The EsoGuard Esophageal DNA Test assesses signature epigenetic changes indicative of BE and EAC using advanced molecular diagnostic techniques.
03
Results
The physician receives a report with a positive or negative result indicating whether or not epigenetic changes consistent with BE/EAC were detected.
Meet the team behind the test
Researchers, Physicians, Scientists, Innovators, Educators
EsoGuard was developed through the National Cancer Institute and arose from a collaboration among Case Western Reserve University faculty, including renowned cancer geneticists, a passionate gastroenterologist, and a dedicated pathologist.
SANDY MARKOWITZ, MD
Physician, Department of Hematology and Oncology
Ingalls Professor of Cancer Genetics, Department of Medicine, School of Medicine
Professor, Department of Genetics and Genome Sciences, School of Medicine
Professor, Department of Molecular Biology and Microbiology, School of Medicine
Principal Investigator, Case GI SPORE, Case Comprehensive Cancer Center
Co-Leader, GI Cancer Genetics
Program, Case Comprehensive Cancer Center
Case Western Reserve University
University Hospitals Cleveland Medical Center
AMITABH CHAK, MD
Physician, Department of Gastroenterology, University Hospitals Cleveland Medical Center
Professor, Department of Medicine, School of Medicine
Member, Cancer Genomics and Epigenomics Program, Case Comprehensive Cancer Center
Case Western Reserve University
University Hospitals Cleveland
Medical Center
JOE WILLIS, MD
Vice Chairman of Pathology, Clinical Affairs, Laboratory Director, University Hospitals Cleveland Medical Center
Professor, Department of Pathology, School of Medicine
Member, Cancer Genomics and Epigenomics Program, Case Comprehensive Cancer Center
Case Western Reserve University
University Hospitals Cleveland
Medical Center
REFERENCES:
1. Moinova, Helen R et al. “Multicenter, prospective trial of non-endoscopic biomarker-driven detection of f Barrett’s Esophagus and Esophageal Adenocarcinoma.” The American Journal of Gastroenterology (2024): 10-14309.
2. Greer, Katarina B et al. “Non-endoscopic screening for Barrett’s Esophagus and Esophageal Adenocarcinoma in at risk veterans.” medRxiv (2024): 2024-03 [Preprint.
3. Shaheen, N., et al., Use of the EsoGuard® Molecular Biomarker Test in Non-Endoscopic Detection of Barrett's Esophagus among High-Risk Individuals in a Screening Population. medRxiv, 2024: p. 2024.06.24.24309401.